Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

@inproceedings{Arizumi2014ComparisonOS,
  title={Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma},
  author={Tadaaki Arizumi and Kazuomi Ueshima and Haruhiko Takeda and Yukio Osaki and Masahiro Takita and Tatsuo Inoue and Satoshi Kitai and Norihisa Yada and Satoru Hagiwara and Yasunori Minami and Toshiharu Sakurai and Naoshi Nishida and Masatoshi Kudo},
  booktitle={Journal of Gastroenterology},
  year={2014}
}
BackgroundTo test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS).MethodsThe therapeutic… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma.

  • Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
  • 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Sorafenib in advanced hepatocellular carcinoma.

  • The New England journal of medicine
  • 2008
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL